1393TiP A phase II/III study to evaluate the optimal dose, safety, and efficacy of livmoniplimab (Livmo) in combination with budigalimab (Budi) plus chemotherapy (CT) vs pembrolizumab (Pembro) plus CT in untreated metastatic non-small cell lung cancer (mNSCLC)

Autor:	Girard, N., Zer, A., Raez, L.E., Horinouchi, H., Zugazagoitia, J., Chen, X., Jha, S., Ferlini, C., Ngo, D.
Zdroj:	In Annals of Oncology September 2024 35 Supplement 2:S872-S872
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu